The need of CBD for AIDS is not new knowledge, but it’s still being sought!
Unlike many other diseases, research involving CBD for AIDS is not new. As a matter of fact, Marinol was introduced in the 1980’s. Marinol is primarily a CBD formula. Doctors prescribed (and still do) Marinol to patients with HIV/AIDS and a variety of cancers. Patients with these conditions use Marinol to induce an appetite. Furthermore, it helps to keep food down by alleviating symptoms like nausea and vomiting.
Other research indicates that CBD for AIDS works by non-intrusively stimulating healthy autoimmune activity.
The National Center for Biotechnology Information published an extensive collection of research related to CBD for AIDS as well as HIV. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470840/)
In this literature, professionals outlined a number of studies that have demonstrated CBD’s potential to have a positive impact on autoimmune health and functionality. Furthermore, they noted that medical professionals prefer the option of treating HIV and AIDS with CBD as opposed to THC. This is because when one compares CBD to THC, CBD doesn’t contain the same psychoactive properties.
As research on CBD for AIDS, cancer, and neurological disorders broadens, some leading cannabis product experts are taking steps to ensure cutting edge CBD and THC therapies are available.
In 2015, Cannabis Science announced its involvement with IGXBio on a treatment involving CBD for AIDS. (https://www.prnewswire.com/news-releases/cannabis-science-brings-cs-tati-1-to-the-fda-with-historic-collaborative-drug-development-deal-with-igxbio-and-its-genepro-a-dna-based-immunotherapeutic-that-recently-received-fda-approval-to-enter-into-human-trials-300089330.html)
Cannabis Science is a cannabis provider who not only focuses on AIDS, but on CBD therapy for cancer and a variety of neurological conditions. IGXBio is a private, biotechnology company with a number of cutting edge products.
These industry professionals entered into a ‘Historic Collaborative Drug Development’ deal involving cannabis-based, DNA-targeted immunotherapy. Scientists are still working to develop CS-TATI-1. CS-TATI-1 will use GenePro® technology. GenePro® is an immune-based protein booster that was approved by the FDA for human trials when this development deal began.
Research doesn’t only indicate CBD for AIDS could be effective. As a matter of fact, other research indicates that – if nothing else – neither CBD nor THC is harmful to patients living with HIV or AIDS.
A group of virology and immunology professionals in San Francisco conducted a study related to the effects of both CBD and THC on patients living with HIV/AIDS. (https://www.ncbi.nlm.nih.gov/pubmed/12965981)
They concluded that consuming cannabis did not have a negative impact on CD4+ or CD8+ counts. Therefore, even if CBD for AIDS wasn’t effective in managing symptoms or slowing its progression, at least it’s not causing any additional damage.